In 2012, the company orally presented in Nanjing, China about the symposium of its drug delivery systems, which help improve therapeutic molecules' pharmaceutical properties.
[7] It is also actively researching on improving the chemical attachment of PEG to help provide antibodies in molecules.
[9][10] The products of Enzon Pharmaceuticals, Inc include four principal compounds of different clinical development, as well as several novel mRNA antagonists in preclinical research.
[13] In the same month, the company presented the Phase II study in which PEG-SN38 demonstrated notable activity in patients with previously treated metastatic breast at the American Society of Clinical Oncology Meeting.
[16] The company has recently launched a nationwide recall of OMONTYS injection because of reports on serious hypersensitivity reactions, including possible life-threatening anaphylaxis.